



# Study Companion: Answers to Clinicians' Questions About Biosimilar Use in Inflammatory Conditions



## References


1. US Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product: guidance for industry. <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf> (2015, accessed December 15, 2021).
2. Woodcock J, Griffin J, Behrman R, et al. The FDA's assessment of follow-on protein products: a historical perspective. *Nat Rev Drug Discov*. 2007;6(6):437-442.
3. US Food and Drug Administration. Biological Product Definitions. <https://www.fda.gov/files/drugs/published/Biological-Product-Definitions.pdf> (accessed December 15, 2021).
4. American College of Rheumatology. Biosimilars Position Statement. <https://www.rheumatology.org/Practice-Quality/Administrative-Support/Position-Statements> (February 2021, accessed December 16, 2021).
5. US Food and Drug Administration. Nonproprietary Naming of Biological Products: Guidance for Industry. <https://www.fda.gov/media/93218/download> (2017, accessed December 15, 2021).
6. US Food and Drug Administration. Nonproprietary Naming of Biological Products Update: Guidance for Industry. <https://www.fda.gov/media/121316/download> (2019, accessed December 15, 2021).
7. Peters GL, Hennessey EK. Naming of biological products. *US Pharm*. 2020;45(6):33-36.
8. Lee H. Equivalence margin of the biosimilar product. *J Korean Soc Clin Pharmacol Ther*. 2012;20:17-33.
9. Mielke J, Jilma B, Jones B, Koenig F. An update on the clinical evidence that supports biosimilar approvals in Europe. *Br J Clin Pharmacol*. 2018;84(7):1415-1431.
10. Shin D, Kim Y, Kim HS, Fuhr R, Körnicke T. FRI0110 A phase I pharmacokinetic study comparing SB5, an adalimumab biosimilar, and adalimumab reference product (Humira®) in healthy subjects. *Ann Rheum Dis*. 2015;74:459-460.
11. Weinblatt ME, Baranauskaite A, Niebrzydowski J, et al. Phase III randomized study of SB5, an adalimumab biosimilar, versus reference adalimumab in patients with moderate-to-severe rheumatoid arthritis. *Arthritis Rheumatol*. 2018;70(1):40-48.
12. US Food and Drug Administration. Interchangeable Biological Products. <https://www.fda.gov/media/151094/download>. (accessed December 15, 2021).
13. US Food and Drug Administration. Prescribing Interchangeable Products. <https://www.fda.gov/media/108107/download>. (accessed December 15, 2021).
14. Ferrario A, Humbert T, Kanavos P, Pedersen HB. Strategic procurement and international collaboration to improve access to medicines. *Bull World Health Organ*. 2017;95(10):720-722.
15. Dalen D, Strom S, Locatelli M. Biosimilar bidding in centralized tenders in Norway. *Nordic Journal of Health Economics*. 2021.
16. Sarpatwari A, Avorn J, Kesselheim AS. Progress and hurdles for follow-on biologics. *N Engl J Med*. 2015;372(25):2380-2382.
17. Curto S, Ghislandi S, van de Vooren K, Duranti S, Garattini L. Regional tenders on biosimilars in Italy: an empirical analysis of awarded prices. *Health Policy*. 2014;116(2-3):182-187.
18. McBride A, Balu S, Campbell K, Bikkina M, MacDonald K, Abraham I. Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndz. *Future Oncol*. 2017;13(25):2285-2295.

## Study Companion: Answers to Clinicians' Questions About Biosimilar Use in Inflammatory Conditions



19. Mulcahy AW, Predmore Z, Mattke S. *The Cost Savings Potential of Biosimilar Drugs in the United States*. Santa Monica, CA: RAND Corporation; 2014.
20. Hopson S, Saverno K, Liu LZ, et al. Impact of out-of-pocket costs on prescription fills among new initiators of biologic therapies for rheumatoid arthritis. *J Manag Care Spec Pharm*. 2016;22(2):122-130.
21. Schiestl M, Stangler T, Torella C, Cepeljnik T, Toll H, Grau R. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. *Nat Biotechnol*. 2011;29(4):310-312.
22. US Food and Drug Administration. Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference Product. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/quality-considerations-demonstrating-biosimilarity-therapeutic-protein-product-reference-product> (accessed December 15, 2021).
23. Liu HF, Ma J, Winter C, Bayer R. Recovery and purification process development for monoclonal antibody production. *MAbs*. 2010;2(5):480-499.
24. Li F, Vijayasankaran N, Shen AY, Kiss R, Amanullah A. Cell culture processes for monoclonal antibody production. *MAbs*. 2010;2(5):466-479.
25. Mehr SR, Zimmerman MP. Is a Biologic Produced 15 Years Ago a Biosimilar of Itself Today? *Am Health Drug Benefits*. 2016;9(9):515-518.
26. US Food and Drug Administration. Biosimilar Regulatory Review and Approval. <https://www.fda.gov/media/151061/download> (accessed December 15, 2021).
27. US Food and Drug Administration. Overview of the Regulatory Framework and FDA's Guidance for the Development and Approval of Biosimilar and Interchangeable Products in the US. <https://www.fda.gov/media/109573/download> (accessed January 1, 2022).
28. US Food and Drug Administration. Labeling for Biosimilar Products: Guidance for Industry. Available at <https://www.fda.gov/media/96894/download#:~:text=The%20labeling%20for%20the%20biosimilar,for%20those%20conditions%20of%20use>. Accessed September 22, 2021.
29. World Health Organization. The importance of pharmacovigilance (2002). Available at <https://www.who.int/publications/i/item/10665-42493>. Accessed January 5, 2022.
30. Dorner T, Strand V, Cornes P, et al. The changing landscape of biosimilars in rheumatology. *Ann Rheum Dis*. 2016;75(6):974-982.
31. US Food and Drug Administration. An Introduction to Drug Safety Surveillance and the FDA Adverse Event Reporting System (2018). Available at <https://www.fda.gov/files/about%20fda/published/Drug-Safety-Surveillance-and-the-FDA-Adverse-Event-Reporting-System-%28PDF---1.31MB%29.pdf>. Accessed January 5, 2022.
32. US Food and Drug Administration. Purple Book: Lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations. Available at <https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/purple-book-lists-licensed-biological-products-reference-product-exclusivity-and-biosimilarity-or>. Accessed January 5, 2022.
33. Li E, Ramanan S, Green L. Pharmacist substitution of biological products: Issues and considerations. *J Manag Care Spec Pharm*. 2015;21(7):532-539.
34. Socinski MA, Curigliano G, Jacobs I, Gumbiner B, MacDonald J, Thomas D. Clinical considerations for the development of biosimilars in oncology. *MAbs*. 2015;7(2):286-293.

## Study Companion: Answers to Clinicians' Questions About Biosimilar Use in Inflammatory Conditions



35. Cohen HP. BIOSIMILAR DEVELOPMENT - Approval of Biosimilar Medicines Through Totality of the Evidence. Retrieved from <https://drug-dev.com/biosimilar-development-approval-of-biosimilar-medicines-through-totality-of-the-evidence/>. Accessed January 6, 2022.
36. Tesser JR, Furst DE, Jacobs I. Biosimilars and the extrapolation of indications for inflammatory conditions. *Biologics*. 2017;11:5-11.
37. Hung A, Vu Q, Mostovoy L. A systematic review of U.S. biosimilar approvals: What evidence does the FDA require and how are manufacturers responding? *J Manag Care Spec Pharm*. 2017;23(12):1234-1244.
38. Weise M, Bielsky MC, De Smet K, et al. Biosimilars: what clinicians should know. *Blood*. 2012;120(26):5111-5117.
39. Bhat S, Limdi JK, Cross RK, Farraye FA. Does similarity breed contempt? A review of the use of biosimilars in inflammatory bowel disease. *Dig Dis Sci*. 2021;66(8):2513-2532.
40. Leonard E, Wascovich M, Oskouei S, Gurz P, Carpenter D. Factors affecting health care provider knowledge and acceptance of biosimilar medicines: A systematic review. *J Manag Care Spec Pharm*. 2019;25(1):102-112.
41. Peyrin-Biroulet L, Lonnfors S, Avedano L, Danese S. Changes in inflammatory bowel disease patients' perspectives on biosimilars: A follow-up survey. *United European Gastroenterol J*. 2019;7(10):1345-1352.
42. Teeple A, Ellis LA, Huff L, et al. Physician attitudes about non-medical switching to biosimilars: results from an online physician survey in the United States. *Curr Med Res Opin*. 2019;35(4):611-617.
43. Teeple A, Ginsburg S, Howard L, et al. Patient attitudes about non-medical switching to biosimilars: results from an online patient survey in the United States. *Curr Med Res Opin*. 2019;35(4):603-609.
44. Jacobs I, Singh E, Sewell KL, Al-Sabbagh A, Shane LG. Patient attitudes and understanding about biosimilars: an international cross-sectional survey. *Patient Prefer Adherence*. 2016;10:937-948.
45. Colloca L, Panaccione R, Murphy TK. The clinical implications of nocebo effects for biosimilar therapy. *Front Pharmacol*. 2019;10:1372.
46. Pouillon L, Socha M, Demore B, et al. The nocebo effect: a clinical challenge in the era of biosimilars. *Expert Rev Clin Immunol*. 2018;14(9):739-749.